Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Cancer Research|2006Cited by 106
Global Spread of Norovirus GII.17 Kawasaki 308, 2014–2016Martin C.W. Chan, Paul K.S. Chan, Yunwen Hu et al.|Emerging infectious diseases|2017Cited by 91
Supplementary Figure Legend from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0
Data from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0